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Since  its introduction,  conventional  endoscopy  has  changed  the  management  framework
of  a variety  of  gastrointestinal  tract  (GIT)  diseases  and is  now  considered  a fundamental
component  in the  evaluation  and  treatment  of  gastrointestinal  diseases.  Histologic  analysis
of specimens  remains  the gold  standard  for the  ﬁnal  diagnosis  of  gastrointestinal  lesions.
However,  such  workup  is time-consuming  and  labor-intensive.  This restricts  the  endo-
scopists  to  immediately  determine  the  necessity  for  resection  during  ongoing  endoscopies,
necessitating  the  need  to repeat  the  procedure.  Furthermore,  overtreatment  (resection  of
benign lesions)  or undertreatment  (biopsy  instead  of  resection  for neoplastic  tissue)  can
lead to frustrations,  unnecessary  risks  (e.g.,  bleeding)  for the patients,  and  delay  in  deﬁnite
treatment for  the urgent  cases.
Recently, developments  in endoscopic  and  imaging  technologies  (narrow-band  imaging,
autoﬂuorescence  imaging,  confocal  laser  endoscopy  and  imaging,  optical  coherence  tomo-
graphy, and endoscopic  ultrasound)  can  provide  a wide  variety  of  valuable  tools  for  in vivo
cytological diagnosis  of neoplastic  lesions  of  GIT,  even  beyond  inner  layer  of  the  bowel.  Such
investigations,  may  therefore  lead  to  an  optimized  rapid  diagnosis  of GIT lesions,  provid-
ing important  implications  also  for immediate  therapy,  during  ongoing  endoscopies  (e.g.,
endoscopic  resection  of  neoplastic  tissue).  Moreover  the  possibility  to properly  investigate
in vivo  progression  of  the  extraluminal  disease  (lymph  node  status)  allows  reducing,  if not
eliminating  the  need  of ex
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1. Introduction
Despite a diverse range of emerging developments in
gastrointestinal endoscopic techniques, early cancer can
rarely  be identiﬁed by routine examination. Worldwide,
more than 350,000 new cases with cancer in oropharynx
and hypopharynx are diagnosed and 197,000 annual deaths
from  these cancers are recorded [1,2]. Colorectal cancer
remains one of the leading causes of cancer death in the
western world [3,4] and develops in about 5–6% of the
adult population; almost one half will die as a consequence
of  the disease [5]. The incidence and related mortalities
from colorectal carcinoma have been steadily increasing
in  the Kingdom of Saudi Arabia over the past twenty
years [6]. Such alarming data demands attention to the
novel  developments in diagnostic armamentarium, with
high  accuracy, feasibility, and effectiveness. The present
review outlines the modern technologies with possibilities
of  in vivo cytological analysis, permitting rapid diagnosis
and treatment strategies.
2.  Narrow band imaging
Narrow  band imaging (NBI) is a new optical technol-
ogy that can clearly visualize the microvascular structure of
the  organ surface [7]. Machida et al. performed endoscopic
evaluation of the colonic lesions (by using conventional
colonoscopy, NBI colonoscopy, and chromoendoscopy)
and  II were non-neoplastics and III and IV were neoplastic).
All  suspected lesions were subjected to histological exami-
nation  and the results were compared with the endoscopic
ﬁndings. The accuracy of endoscopic diagnosis compared
with histological ﬁndings was 79.1% and 93.4% with con-
ventional and NBI colonoscopy, respectively. This ﬁnding
underpins the diagnostic accuracy of NBI, which elaborates
its  future role in the detection of GIT lesions.
2.1. Operating system
NBI  involves the placement of narrow-band ﬁlters in
front  of a conventional white light source to capture tis-
sue  illumination at selected narrow wavelength bands.
The  propagation of light depends on its wavelength Blue,
having  a shorter wavelength, diffuses in a smaller range,
whereas red, possessing a longer wavelength, diffuses
widely and deeply. The blue ﬁlter is designed to corre-
spond to the peak absorption spectrum of hemoglobin
to emphasize the image of capillary vessels on surface
mucosa [9–12]. The NBI systems currently available use 2
narrow-band ﬁlters that provide tissue illumination in the
green  (540 nm)  and blue (415 nm)  spectrum of light [13].
Deeper  mucosal and submucosal vessels made visible by
the  540-nm light appear cyan, whereas capillaries in the
superﬁcial mucosal layer are emphasized by the 415-nm
light  and appear brown (Fig. 1). The ﬁnal composite NBIfocusing on mucosal pit pattern and the shape of colonic
crypt oriﬁces [8]. NBI was able to clearly distinguish
between neoplasia and non-neoplastic lesions according
to  the pit patterns (following Kudo’s classiﬁcation types 1is  reconstructed from the 415-nm image in the blue and
green  channels and the 540-nm image in the red chan-
nel  of the monitor [14]. The NBI ﬁlter sets (415–30 nm,
445–30 nm,  500–30 nm)  are selected to obtain ﬁne images












































hFig. 1. Narrow Banding Imaging (NBI) physical basis.
f the microvascular structure. Because the 415-nm is the
emoglobin absorption band, the thin blood vessels such as
apillaries  on the mucosal surface can be seen most clearly
n  this wavelength [15]. Light with short wavelength is
ithin  the hemoglobin absorption band, so that blood ves-
els  may  be demonstrated with sufﬁcient contrast against
he  normal background [14,15].
.2. Clinical applications
Per  se, GIT malignancies originate from the gastroin-
estinal mucosa, which necessitates precise endoscopic
valuation to detect early lesions, before they progress to
n  advanced stage (Fig. 2A and B). NBI is useful in elaborat-
ng  the following:
.2.1.  Increased microvessels in the neoplastic epithelium
Angiogenic features of the GIT neoplastic lesions is a
allmark of NBI endoscopy, which illustrates increased
icrovessels in the neoplastic epithelium, whereas normal
pithelium contains few microvessels [16]. Microcapillary
essels in normal mucosa or on the surface of hyperplas-
ic lesions are arranged in a honeycomb pattern around
ucosal crypts without any change in vessel diameter,
ut the capillaries in neoplastic lesions become elon-
ated with larger diameters as the number and density of
icrocapillary vessels increase during the transition from
remalignant to malignant lesions [17]. Sano et al. labeled
he  mucosal capillary mesh arranged in a honeycomb pat-
ern  around mucosal crypts as ‘meshed capillary vessels’
18].  By identifying meshed capillary vessels pattern, the
esearchers were able to develop a sequential method using
BI  for more frequent detection of abnormal microcapillar-
es as indicators of neoplasia.
A  recent study using NBI with magniﬁcation, the
icrovascular architecture observed on the surface of the
etected  lesions, capillary patterns (CP), was divided into
on-neoplastic (CP I) and neoplastic (CP II and CP III) types
19].  Ninety-seven per cent (N = 103) of colorectal neo-
lastic lesions with CP II were histologically diagnosed as
ow-grade  dysplasia. Eighty-seven per cent (N = 31) of the
olorectal  neoplastic lesions with CP III were high-grade
ysplasia or invasive cancer.
.2.2.  Carcinoma in situ of the oropharynx and
ypopharynx
Muto et al., by using NBI, examined the upper GIT lesions
uring routine endoscopic screening and surveillance of
00  individuals [7]. More than 50 superﬁcial lesions could
e  detected by NBI. Among them, 41 superﬁcial lesions
ere endoscopically removed; twenty-nine lesions were
istologically conﬁrmed to be carcinoma in situ, and they and Ultrastructure 1 (2013) 65–75 67
remainder exhibited cancer with microinvasion beneath
the  epithelium (Fig. 2A and B).
2.2.3. Colonic adenoma detection
A study reported that NBI produces greater color con-
trast between adenomas and the surrounding normal
mucosa than does the white light used in conventional
imaging [20]. Imaged in blue light, blood vessels on the
surface of polyps, particularly adenomas, generate a sharp
color  contrast with the surrounding normal mucosa, which
can  enhance detection of lesions. The pan-colonic NBI sys-
tem  improves the total number of adenomas detected,
including signiﬁcantly more diminutive adenomas, with-
out  prolongation of extubation time. These results indicate
that  routine use of the NBI system for surveillance of
diminutive adenomas may  be recommended [16].
2.2.4. Early colorectal neoplasia
Katagiri  et al. conducted a prospective study to evalu-
ate whether different CP (CP type II and CP type III) visible
during NBI with magniﬁcation provided sufﬁciently high
reliability for distinguishing adenomas from intramucosal
and invasive cancers [19]. The overall diagnostic accuracy,
sensitivity and speciﬁcity of their results were 95.5%, 90.3%
and  97.1%, respectively.
2.2.5.  Depth and extent of invasion of the colorectal
cancer
Ikematsu et al. reported that the sensitivity, speciﬁcity
and diagnostic accuracy of CP types IIIA and IIIB for dif-
ferentiating intramucosal or slight submucosal invasion
(<1000 mm from deep submucosal invasion) were 84.8%,
88.7%  and 87.7%, respectively [21]. This information pro-
vides  a valuable roadmap for surgeons and physicians to
devise  a multi-disciplinary treatment strategy for colorec-
tal  cancer.
3.  Autoﬂuorescence imaging
Autoﬂuorescence imaging (AFI) may  detect dysplasia
and neoplasia in upper GIT lesions especially in Barrett’s
esophagus. In AFI, tissue is illuminated with a light source,
mostly in the near-UV to green range of the spectrum,
and images of the ﬂuorescence produced in the tissue are
altered  by absorption, and scattering events are recorded
using a camera [22]. When AFI is used, nondysplastic
Barrett’s esophagus appears green, whereas dysplastic or
neoplastic  lesions appear blue or violet. In addition to its
role  in identifying gastrointestinal neoplasia, AFI has an
established role in diagnosing a wide range of ophthal-
mological diseases [23]. The use of ﬂuorescent contrast
medium is another viable option in AFI.
3.1. Operating system
The  autoﬂuorescence endoscopy system (Olympus
Optical Co., Ltd., Tokyo, Japan) includes a high-resolution
videoendoscope and an AFI technology. It has a xenon
light source, with a rotary red/green/blue band-pass ﬁlter.
With  this light source, the mucosa is sequentially illumi-
nated with red, green, and blue light at a frequency of
68 A. Forgione, S.Y. Guraya / Journal of Microscopy and Ultrastructure 1 (2013) 65–75
 endoscFig. 2. (A) Conventional
20 cycles per second [24]. The high-resolution videoen-
doscope in this system has two separate monochromatic
charge-coupled devices; one for white-light endoscopy
(WLE), and one for AFI (Fig. 3). In the WLE  mode, the
reﬂected red, green, and blue light is detected by the
standard charge-coupled devices and is converted to an
electronic signal that is passed to the videoprocessor. The
processor  electronically overlays the red, green, and blue
signals  to produce high-quality white-light images. WLE
and  AFI can be alternated by means of a switch located
conveniently on the endoscope. During endoscopic exam-
ination,  still images of all suspicious lesions are taken,
following 2–4 biopsies from each area.3.2. Clinical applications
Since  the discovery of the potential of AFI for the detec-
tion of oral cancer, many evidence-based studies have been
Fig. 3. Autoﬂuorescence physical basis. Physical basis of autoﬂuorescence
imaging which utilizes xenon light source, with a rotary red/green/blue
band-pass ﬁlter. With this light source, the mucosa is sequentially illu-
minated with red, green, and blue light at a frequency of 20 cycles per
secondopic view. (B) NBI view.
performed for the oral cavity and the rest of the upper
aerodigestive tract especially Barrett’s esophagus (Fig. 4A
and  B). This technique has demonstrated great promise in
the  following aspects [25]:
(1) Capability in providing a higher contrast between a
lesion and (surrounding) healthy tissue than white light
inspection.
(2) Ability in differentiating between different types of
lesions, in particular benign, dysplastic and malignant.
(3) Efﬁcacy in identifying unknown lesions and unknown
extensions of known lesions, which is useful for tumor
demarcation
Kulapaditharom et al. examined 31 normal and 35
inﬂammatory sites; 4 granulomas, 15 dysplastic and 13
neoplastic lesions in the head and neck region through
an endoscope using 442 nm excitation [26]. Out of these,
19  lesions were identiﬁed in the oral cavity, of which 8
were  either dysplastic or neoplastic. Betz et al., by using
375–440 nm excitation for AFI, studied 30 patients with
tumors of the oral mucosa or oropharynx, and reported
sufﬁcient to excellent demarcation by lower ﬂuorescence
intensity in 20 tumors [27]. However, 10 tumors were not
distinguishable from their host tissues. These tumors were
all  located at the tongue, the soft palate or the tonsillar
sinus. Generally, ﬂat epithelial lesions were found to be
outlined subjectively better by AFI than large, exophytic
tumors. Although high sensitivities and speciﬁcities have
been  obtained using porphyrin-like ﬂuorescence [28,29],
other  studies have claimed that red ﬂuorescence is not
speciﬁc for malignancies [30]. AFI has also been found to
be  an excellent tool in the diagnosis of precancerous and
cancerous laryngeal lesions of the larynx [31].4. Confocal laser endoscopy
The  confocal laser endoscope (CLE) is a novel diagnostic
tool to analyze living cells during endoscopic examinations,




















cFig. 4. (A) Conventional endoscopic view. (B) Endoscopic auto
hus enabling virtual histology of neoplastic changes with
igh  accuracy [32]. These emerging technologies may  be
f  signiﬁcant importance in clinical practice, and may  lead
o  an accurate, reliable, and rapid in vivo diagnosis of neo-
lastic  lesions.
.1.  Operating system
The  components of the confocal laser colonoscope are
ased  on incorporation of a confocal laser microscope in the
istal  tip of a conventional video colonoscope (EC3870K;
entax, Tokyo, Japan), which enables confocal microscopy
n  addition to standard videoendoscopy (Fig. 5). Laser
canning confocal microscopy is an adaptation of light
icroscopy whereby focal laser illumination is combined
ith pinhole limited detection to geometrically reject
ig. 5. Confocal laser microscopy physical basis. Confocal laser
icroscopy with illustration of its physical basis. This system integrates
he adaptation oﬂight microscopy, where focal laser illumination is com-
ined with pinhole-limited detection to geometrically reject out-of-focus
ight. An argon ion laser delivers an excitation wavelength of 488 nm,  and
onfocal images are collected at a scan rate of 0.8 frames/s.ence view of suspicious Barrett esophagus (blue violet area).
out-of-focus light [32]. During laser endoscopy, an argon
ion  laser delivers an excitation wavelength of 488 nm,  and
confocal  images are collected at a scan rate of 0.8 frames/s
(1024 × 1024 pixels) or 1.6 frames/s (1024 × 512 pixels)
(Fig. 5) [33].
4.2.  Clinical applications
Whereas  the nuclei of the intestinal epithelial cells are
not  readily visible during confocal endoscopy because of
the  pharmacologic properties of ﬂuorescein sodium, CLE
demonstrates a more prismatic appearance of intestinal
epithelial cells in vivo, as compared with formalin-ﬁxed
biopsy tissue, inﬂuenced by the absence of ﬁxation arti-
facts.  In the normal colon, CLE shows regular distribution
of round-shaped crypts with round or oval crypt openings
and  a normal number of goblet cells. With CLE, intraep-
ithelial neoplasm and colon cancers display tubular, villous,
or  irregular architecture with a reduced number or loss of
goblet  cells. A unique gap between the cells indicates loss of
cellular  junction due to loss of tight junctions as a potential
sign  of early malignancy [32]. Dilated and distorted vessels
with  marked leakage and irregular architecture with little
or  no orientation to adjunct tissue is another hallmark of
malignancy (Fig. 6A and B).
During colonoscopy, CLE is ﬁrst introduced into the
terminal ileum or cecum, and a total of 5 mL  ﬂuores-
cein (5–10 mL  of a 10% solution; Alcon Laboratories, Inc.)
sodium and 2 mL  butylscopolamine (Buscopan; Boehringer
Ingelheim, Germany) is then given intravenously, because
peristalsis may  lead to artifacts. On withdrawal, all parts of
the  colon are examined systematically. Standardized loca-
tions  (every 10 cm in the colon and the distal part of the
ileum)  and every macroscopically visible lesion are exam-
ined  with the help of the CLE imaging system. Every ﬂat
or  suspected lesion is stained before the confocal exam-
ination in a targeted fashion by using methylene blue at
a  ﬁnal concentration of 0.1% to clarify the borders of the
lesions. In addition, the distal 20 cm of the colon is stained
in  an untargeted fashion with methylene blue. After CLE,
all  patients develop a slight yellow coloration of the skin (a
70 A. Forgione, S.Y. Guraya / Journal of Microscopy and Ultrastructure 1 (2013) 65–75
. (B) Co
of  this layered structure and a thickening of the epithelial
surface, leading to thicker airway walls (probe diameter
1.5 mm,  4 B-scans/s, 16 lm axial resolution in air) [39].
Endoscopic OCT entails detailed imaging of the mucosal
Fig. 7. Optical coherence tomography physical principle. Physical princi-
ples of optical coherence tomography, which implies near infrared lightFig. 6. (A) Endoscopic view of the probe
side effect of ﬂuorescein sodium), which disappears in all
cases  within 60 min.
5. Optical coherence tomography
The technique of optical coherence tomography (OCT),
by  using ﬁber-optic probe, enables the acquisition of very
high-resolution images, allowing imaging of individual
cells. Such imaging is of a much higher resolution than is
possible  with other clinical modalities, such as CT, MRI  or
ultrasound, and is more similar to the level of detail achiev-
able  by histology [34].
5.1.  Operating system
OCT  is an interferometric imaging strategy that is anal-
ogous  to ultrasound but implies near infrared light waves
instead of sound waves. Light from a broadband source is
split  into two channels by an optical beam splitter [35].
First  channel, the reference arm, is terminated by a mirror,
which  reﬂects light back along the path. Second channel,
the  sample arm, is weakly focused into the tissue sample
under examination (Fig. 7). A small percentage of the light
is  backscattered from multiple depths within the tissue and
captured  by the system. Reﬂected light from the reference
arm and backscattered light from the sample arm are com-
bined,  and light that has traveled the same optical path
length in both arms, to within the short coherence length,
is  coherently interfered, giving a signal indicative of the
backscatter from a particular depth in the tissue sample
[36]. By varying the optical path length of the reference
arm, we can attain the tissue backscatter at varying depths.
Endoscopic OCT probes typically consist of a length of
single  mode ﬁber encased in a protective plastic catheter.
Attached to the distal end of the probe is focusing optics,
often a small GRIN lens. Majority of the miniaturized
probes described in the literature are side-facing, and
will  have some mechanism to deﬂect the light beam
perpendicular to the axis of the probe, either through the
use  of a mirror or a prism via total internal reﬂection.
In OCT contrast enhancement, backscatter enhancing
contrast agents based on gold nanoparticles [37] andnfocal microscopic view of the mucosa.
encapsulating microspheres containing scattering or
absorbing nanoparticles are being developed [38].
5.2.  Clinical applications
OCT,  a non-invasive optical imaging technique, pro-
vides high-resolution cross-sectional images of tissue
microstructure. By using OCT, early in vivo human research
has  shown its potential of differentiating between healthy
and  pathologic airway wall structure. Endoscopic OCT
imaging showed normal bronchus to have a uniform lay-
ered  structure. In contrast, areas of tumor showed a losswaves, which is split into two channels by an optical beam splitter.
Reﬂected light and backscattered light are combined, and light that has
traveled the same optical path length in both arms, to within the short
coherence length, is coherently interfered, giving a signal indicative of
the  backscatter from a particular depth in the tissue sample.






























eFig. 8. OCT images of the inner layer of the bowel.
nd submucosal structures of the human GIT (Fig. 8), and
as  also been demonstrated on the esophagus, stomach,
uodenum, terminal ileum, colon and rectum [40,41], uri-
ary  tract [42], macular lesions [43], and coronary imaging
44].  In particular, there has been signiﬁcant research in the
pplication  of endoscopic OCT probes to the diagnosis and
onitoring of Barrett’s esophagus [45].
Because the degree of OCT reﬂectivity depends upon
uclear size, a markedly inhomogenous and hypo-
eﬂective backscattering of the signal indicates disorga-
ized tissue architecture and the presence of high-grade
ysplasia. OCT features predictive of the presence of intesti-
al  metaplasia are [46]:
1) Absence of the layered structure of the normal squa-
mous epithelium and the presence of the vertical
crypt-and-pit  morphology of normal gastric mucosa
2) Disorganized architecture with inhomogeneous
backscattering of the signal and an irregular mucosal
surface
3) Presence of submucosal glands characterized at the
OCT image as pockets of low reﬂectance below the
epithelial surface
These OCT criteria applied to images acquired prospec-
ively, were found to be 97% sensitive and 92% speciﬁc for
pecialized intestinal metaplasia, with a positive predictive
alue  of 84% [47]. Despite the potential of this technology,
CT imaging has been restricted in clinical applications by
ts  extremely limited imaging depth, typically only 2–3 mm
n  tissue. Fiber bundles have been used to demonstrate
ndoscopic OCT applications, but equalizing delays across
uch  a large number of ﬁbers in a ﬂexible bundle has proven
roblematic to date [48].
.  Endocytoscopy
Endocytoscopy, an ultra-high magniﬁcation tech-
ique, enables surface morphology to be assessed with
agniﬁcations in excess of 450× in real time [49]. This
aluable device can be used throughout the GIT, enabling
urther characterization of pathology such as dysplasia or
arly  cancer in Barrett’s esophagus, villous and cellularFig. 9. Endocytoscope probe.
morphology in patients with suspicion of celiac disease, or
assessing  and differentiating colonic polyps in real time.
Latest  developments in technologies permits to per-
form microscopic imaging of living cells from both normal
mucosa and malignant tissue in the GIT [50]. Endocy-
toscopy is a catheter-type contact endoscope that has more
than  1000-fold magnifying power and can pass through the
working  channel of the straight-view endoscope (Fig. 9).
The  nucleus, cell body, and even the nucleolus can be
clearly distinguished with high-resolution images, com-
parable  with those of conventional cytology. This unique
technology has the potential to provide in vivo histo-
logic diagnoses during endoscopic examinations, similar to
those  obtained currently by conventional histology tech-
niques.Fig. 10. Ultrasonography physical principle.
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stinal mFig. 11. (A) Endoscopic ultrasonographic features of inte
6.1. Operating system
The  target tissue is ﬁrst stained by the application
of a double stain technique, which approximates hema-
toxylin and eosin staining in conventional histology. The
target  area is ﬁrst treated with a mucolytic agent, 10%
N-acetylcysteine, followed by an application of 1% methy-
lene  blue, which stains the nucleus, and 0.1% crystal violet,
which  stains nucleus as well as the cytoplasm. The endo-
cytoscope probe is then maneuvered through the working
channel and is gradually progressed until the tip approxi-
mates the mucosa.6.2.  Clinical applications
Potential  applications of the endocytoscope include the
identiﬁcation of dysplastic or early cancerous lesions inucosa. (B) Correspondence of bowel wall layers and EUS.
premalignant conditions of the GIT, histological differen-
tiation of serrated polyps [51] and inﬂammatory bowel
disease (IBD) [52]. In IBD the following clinical implications
of  endocytoscopy have been reported:
(1) Differential histologic changes of Crohn’s disease (CD)
and Ulcerative colitis (UC) in vivo in real time, allowing
for a targeted and tactical biopsy approach.
(2)  Discrimination of mucosal inﬂammatory cells during
endoscopy, thus determining the histopathologic activ-
ity of UC.
(3) Molecular imaging with ﬂuorescence-labeled probes
against disease-speciﬁc receptors, enabling individual-
ized management of patients with IBD.
A  study revealed similarities between endocytoscopic
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ormal squamous cells in the esophagus [53]. The obvious
ifference in nuclear and structural atypia and nuclear den-
ity  made it possible to diagnose them without endoscopic
iopsy. Although endocytoscopic images closely correlated
ith  conventional histology in the esophagus, appropriate
reconditioning to constantly obtain sufﬁcient image qual-
ty  and universal criteria for endocytoscopic diagnosis of
arious  diseases are essential before clinical application.
.  Endoscopic ultrasound
In  physics, the term “ultrasound” applies to all sound
aves with a frequency above the audible range of normal
uman hearing, about 20 kHz. The frequencies used in diag-
ostic  ultrasound are typically between 2 and 18 MHz. A
ound  wave is typically produced by a piezoelectric trans-
ucer  encased in a housing which can take a number of
orms.  Strong, short electrical pulses from the ultrasound
achine make the transducer resonate at the desired fre-
uency.  The sound is focused either by the shape of the
ransducer, a lens in front of the transducer, or a com-
lex set of control pulses from the ultrasound scanner.
he wave travels into the body and comes into focus at
 desired depth. The sound wave is partially reﬂected from
he  layers between different tissues. Speciﬁcally, sound is
eﬂected  anywhere there are density changes in the body:
.g.,  blood cells in blood plasma, small structures in organs,
tc.  Some of the reﬂections return to the same piezoelectric
ransducer that ﬁnally turns the vibrations once again into
lectrical  pulses that will be processed and transformed
nto a digital image (Fig. 10).
Endoscopic ultrasound (EUS) was initially developed
n the early 1980s primarily to overcome the limitations
f transabdominal ultrasound in imaging the pancreas. In
US,  a small high-frequency ultrasound transducer is incor-
orated  into the tip of a ﬂexible endoscope.
The fundamental importance of EUS is its ability to
rovide information of the transmural status and layered
ramework of the GIT; mucosa through serosa and beyond.
.1.  Operating system
Radial  scanning echoendoscopes were initially most fre-
uently  used for EUS. The ultrasound transducer rotates to
rovide  a 360-degree cross-sectional image. Viewing fre-
uencies  between 5 and 20 MHz  can be used. A balloon with
ater-ﬁlling capacity encases the ultrasound transducer at
he  tip of the endoscope. The water in the balloon helps
vercome the difﬁculty of imaging in an air-ﬁlled lumen.
olid-state radial EUS instruments, without rotating parts,
ave  been introduced more recently. Linear array echoen-
oscopes provide ultrasound images along the long axis of
he  echoendoscope. This type of echoendoscope provides a
inear  array view along the axis of the needle as is required
or  interventional EUS.
Endoscopic ultrasound provides a detailed view of the
astrointestinal wall layers, which appear as alternating
right and dark bands. These layers include (1) superﬁcial
ucosa (hyperechoic); (2) deep mucosa (hypoechoic); (3)
ubmucosa  (hyperechoic); (4) muscularis propria (hypoe-
hoic);  and (5) serosa (hyperechoic) (Fig. 11A and B).y and Ultrastructure 1 (2013) 65–75 73
Alternatively EUS can be performed using miniprobes
and wire-guided catheter probes that can be inserted
through the operative channel of conventional endoscope.
Today commercial 3D-EUS systems are available.
7.2. Clinical applications
EUS  is classically indicated for the following GIT ail-
ments;
(1)  Staging of cancers; esophageal, pancreatic, gastric, bile
duct, papilla of Vater, and rectum
(2)  Evaluation of submucosal lesions
(3)  Evaluation of extramural abnormalities
(4)  Evaluation of pancreatic lesions
(5)  Evaluation of thickened gastric folds
(6)  Evaluation and EUS-guided FNA of lesions adjacent to
esophagus, stomach, duodenum, and rectum
(7)  Chronic pancreatitis
(8) Detection of common bile duct stones
When  the gastrointestinal wall is examined with a
miniprobe at higher frequencies (20 MHz), 9 endosono-
graphic layers can be visualized [54] as shown in. The
mucosa consists of 4 layers: 1st and 2nd layers represent
the epithelium, 3rd layer lamina propria, and 4th layer
being the muscularis mucosa. The 5th layer constituted by
the  submucosa, The muscularis propria contains three lay-
ers:  the 6th layer is circular muscle, 7th layer is connective
tissue between the circular and longitudinal muscle, and
8th  layer is the longitudinal muscle. Finally, 9th layer is
the  adventitia. Hence, early and/or advanced histological
changes in the GIT structures would be easily illustrated by
EUS  (Fig. 11).
EUS-guided FNA is increasingly being used for the diag-
nosis  and staging of various cancers because it provides
a  minimally invasive alternative to surgical procedures to
obtain  tissue diagnosis and has a sensitivity and speci-
ﬁcity that is better than or at least equal to radiographic
imaging alone. EUS-guided FNA is more sensitive (88% vs.
57%)  and speciﬁc (91% vs. 82%) than CT [54,55]. The accu-
racy  of transrectal EUS for T staging ranges from 80% to
95%,  compared with 65% to 75% for CT, and 75% to 85%
for  MRI  [56,57]. Harewood and Wiersema [58] reported
that the most cost-effective strategy for evaluation of non-
metastatic rectal cancer was  a combination of abdominal
CT and transrectal EUS. In a prospective study of 80 patients
with  non-metastatic rectal cancer, EUS resulted in the
change of management in 31% of the patients [59].
Another dimension of EUS is its therapeutic poten-
tial in a wide range of procedures, such as celiac plexus
block, stent placement in pancreatic pseudocysts, failed
CBD–pancreatic duct cannulations, and chemotherapy
[60–62]. EUS has been used to perform celiac plexus block
or  neurolysis in patients with chronic pancreatitis and pan-
creatic  cancer [63].8.  Conclusion
The usefulness and efﬁcacy of the above-described tech-
nologies in the detection and cytological examination of
















Gastrointestinal Endoscopy 2005;61(6):679–85.Fig. 12. Proper indication for advanced in vivo diagnostic technologies.
A schematic diagram for the practical applications of the technologies in
terms  of GIT layers and mural thickness
the GIT abnormalities spring from the fact that they avoid
repeat  endoscopies, provide in vivo cytological diagnosis
with accuracy, and help the treating physicians in timely
planning of the multi-disciplinary strategy. A practical
algorithm for the natural and logical application of these
technologies is illustrated in (Fig. 12). This schematic dia-
gram  would certainly allow the physicians in selecting the
appropriate investigation for the patients. More evidence-
based research is needed to evaluate the global acceptance
of  these modern tools in terms of cost-effectiveness, feasi-
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